News
ANL
15.78
+0.25%
0.04
Weekly Report: what happened at ANL last week (0907-0911)?
Weekly Report · 09/14 09:21
Adlai Nortye Group Price Target Announced at $31.00/Share by Jefferies
Dow Jones · 09/10 12:29
Jefferies Initiates Coverage On Adlai Nortye with Buy Rating, Announces Price Target of $31
Benzinga · 09/10 12:19
Adlai Nortye initiated with a Buy at Jefferies
TipRanks · 09/10 10:21
Adlai Nortye Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 09/08 16:06
HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $20 Price Target
Benzinga · 09/08 15:57
Adlai Nortye: Buy Rating Reiterated as RAS-Targeted Pipeline Advances; $20 Price Target Maintained
TipRanks · 09/08 15:55
Adlai Nortye Receives FDA Clearance For AN4035 Phase I Trial
NASDAQ · 09/08 13:38
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035
TipRanks · 09/08 12:28
Adlai Nortye Price Target Announced at $49.00/Share by LUCID CAPITAL MARKETS
Dow Jones · 09/08 12:16
Adlai Nortye Coverage Assumed by LUCID CAPITAL MARKETS at Buy
Dow Jones · 09/08 12:16
Adlai Nortye doses first patient in AN4035 trial
TipRanks · 09/08 11:15
Adlai Nortye assumed with a Buy at Lucid Capital
TipRanks · 09/08 10:45
Weekly Report: what happened at ANL last week (0831-0904)?
Weekly Report · 09/07 09:19
These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts
TipRanks · 09/06 10:00
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
Seeking Alpha · 09/01 14:25
Weekly Report: what happened at ANL last week (0824-0828)?
Weekly Report · 08/31 09:21
Oppenheimer Sticks to Their Buy Rating for Adlai Nortye Ltd. Sponsored ADR (ANL)
TipRanks · 08/27 12:55
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF) and Adlai Nortye Ltd. Sponsored ADR (ANL)
TipRanks · 08/27 12:30
Major Insider Move Shakes Up Adlai Nortye’s Market Narrative
TipRanks · 08/27 02:13
More
Webull provides a variety of real-time ANL stock news. You can receive the latest news about Adlai Nortye Group Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ANL
Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment.